By Abigail Townsend
Date: Monday 23 Feb 2026
(Sharecast News) - Shares in Arcellx soared on Monday, after the US biotech agreed to be taken over by Gilead Sciences in a near $8bn deal.
Under the terms of the deal, California-based Gilead will pay $115 per share in cash and one contingent value of $5 per share, giving Arcellx...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news